Table 1. Patient and Treatment Characteristics.

BCL-U: B-cell lymphoma - unclassifiable; BIA-ALCL: breast implant-associated anaplastic large T-cell lymphoma; CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; ECOG: Eastern Cooperative Oncology Group

Characteristics	All Patients  n (%)	Indolent  n (%)	Aggressive  n (%)	P-value
Age (year), median (range)	66 (34 – 95)	66 (34 – 83)	67 (49 – 95)	0.46
Age > 65	21 (58.3)	12 (52.2)	9 (69.2)	0.48
Male	1 (2.8)	0 (0)	1 (7.7)	0.36
Female	35 (97.2)	23 (100)	12 (92.3)	0.47
White ethnicity	35 (97.2)	22 (95.7)	13 (100)	1
African American	1 (2.8)	1 (4.3)	0 (0)	0.65
Clinical presentation at diagnosis
Abnormal screening mammogram	22 (61.1)	18 (78.3)	4 (30.8)	0.005
Breast lump/swelling	14 (38.9)	5 (21.7)	9 (69.2)	0.005
B-symptoms	2 (5.6)	1 (4.3)	1 (7.7)	0.67
ECOG performance score at diagnosis				0.31
0 or 1	34 (94.4)	22 (95.7)	12 (92.3)
2	1 (2.8)	1 (4.3)	0 (0)
3	1 (2.8)	0 (0)	1 (7.7)
Laterality of tumor				0.69
Right	14 (38.9)	9 (39.1)	5 (38.5)
Left	17 (47.2)	10 (43.5)	7 (53.8)
Bilateral	5 (13.9)	4 (17.4)	1 (7.7)
Stage at diagnosis				0.74
IE	27 (75.0)	18 (78.3)	9 (69.2)
IIE	6 (16.7)	3 (13.0)	3 (23.1)
IV	3 (8.3)	2 (8.7)	1 (7.7)
Histologic type				–
Marginal zone	12 (33.3)	12 (52.2)	0 (0)
Diffuse large B cell lymphoma	9 (25.0)	0 (0)	9 (69.2)
Follicular lymphoma	7 (19.4)	7 (30.4)	0 (0)
CLL/SLL	3 (8.3)	3 (13.0)	0 (0)
BIA-ALCL	2 (5.6)	0 (0)	2 (15.4)
BCL-U (DLBCL or Burkitt lymphoma)	2 (5.6)	0 (0)	2 (15.4)
Nodular sclerosing Hodgkin lymphoma	1 (2.8)	1 (4.3)	0 (0)
Treatment types
Observation	6 (16.7)	6 (26.1)	0 (0)	0.07
Chemotherapy only	9 (25.0)	6 (26.1)	3 (23.1)	0.84
Radiotherapy only	7 (19.4)	5 (21.7)	2 (15.4)	0.64
Surgery only	2 (5.6)	1 (4.3)	1 (7.7)	1
Surgery/chemotherapy	2 (5.6)	1 (4.3)	1 (7.7)	1
Chemotherapy/radiotherapy	8 (22.2)	2 (8.7)	6 (46.2)	0.009
Surgery/radiotherapy	1 (2.8)	1 (4.3)	0 (0)	1
Surgery/chemotherapy/radiotherapy	1 (2.8)	1 (4.3)	0 (0)	1